Prolia® (denosumab)
for Osteoporosis
Prolia (denosumab) is a monoclonal antibody that targets and inhibits RANK ligand (RANKL). It treats osteoporosis in postmenopausal women and men at high fracture risk, glucocorticoid-induced osteoporosis, and increases bone mass in men receiving androgen deprivation therapy for prostate cancer or women receiving aromatase inhibitor therapy for breast cancer. Prolia prevents osteoclast formation, reducing bone resorption and increasing bone mass and strength.
